Jody joined The Health Policy Partnership in January 2018 as Associate Director, and was promoted to the role of Director of Research and Policy in October 2019.Leading numerous research projects across the company, Jody’s role at HPP has included policy initiatives in the areas of vaccination, atrial fibrillation, vaccination, osteoporosis, atrial fibrillation, antimicrobial resistance and BRCA-related breast cancer among others.Jody has more than ten years’ experience in public health and health policy, focusing on research and project management. Much of her work prior to joining HPP involved supporting clients to design, deliver and evaluate large-scale public health programmes in Africa and Asia, with a focus on health systems strengthening, access to medicines and communicable disease control.She has written or contributed to a range of reports and policy briefs for clients, including the UK and Australian governments, the United Nations, and philanthropic organisations.Jody has a Master’s in Public Health (Global Health) from the University of Manchester and a Master’s in Development Studies from the University of London’s School of Oriental and African Studies.
2019Vaccination beyond childhood brings significant benefits at the individual, community and socio-economic levels. Despite this, immunisation programmes often fail to deliver the vaccines which could protect those at risk of vaccine-preventable diseases.
2019The life-course approach to immunization recognizes the role of immunization as a strategy to prevent diseases and maximize health over one’s entire life, regardless of an individual’s age. A life-course approach requires that immunization schedules and access to vaccination respond to an individual’s stage in life, their lifestyle and specific vulnerabilities/risks to infectious disease that they may face.
2019Genetic mutations in the BRCA1 and BRCA2 genes put women at significant risk of developing breast cancer. Most women have a 12.5% risk of developing breast cancer in their lifetime. This risk increases to 60–90% among women with a BRCA1 mutation and 45–85% among women with a BRCA2 mutation.
White Paper on inequalities and unmet needs in the detection of atrial fibrillation (AF) and use of therapies to prevent AF-related stroke in EuropeThe Health Policy Partnership
2018Atrial fibrillation (AF) is the most common sustained heart rhythm disturbance (arrhythmia). People with AF are three to five times more likely to suffer a devastating, debilitating, disabling and often fatal stroke than people without AF. Yet it is widely under-recognised by the general public and policymakers.
Regulation of Anti-Malarial Commodities with a focus on Artemisinin- Combination Therapy (ACTs) the in Asia and Pacific regionEmPower School of Health
2014Drug regulation is a public policy response to the perceived problems or perceived needs of society. Consequently, drug laws need to be updated to keep pace with changes and new challenges in their environment.
Area of Expertise
University of Manchester : Public Health, Distinction
University of London, School of Oriental & African Studies : Development Studies, Merit
University of Leeds : Politics & Sociology